Arrowpoint Investment Partners Singapore Pte. Ltd. Purchases Shares of 9,992 Twist Bioscience Corporation $TWST

Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new stake in shares of Twist Bioscience Corporation (NASDAQ:TWST) during the fourth quarter, Holdings Channel reports. The fund purchased 9,992 shares of the company’s stock, valued at approximately $317,000.

A number of other institutional investors have also bought and sold shares of TWST. Royal Bank of Canada boosted its position in Twist Bioscience by 11.8% during the first quarter. Royal Bank of Canada now owns 40,373 shares of the company’s stock valued at $1,585,000 after acquiring an additional 4,254 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Twist Bioscience by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,310 shares of the company’s stock valued at $2,765,000 after acquiring an additional 3,181 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in Twist Bioscience by 4.2% during the first quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company’s stock valued at $36,629,000 after acquiring an additional 37,577 shares during the last quarter. Intech Investment Management LLC boosted its position in Twist Bioscience by 18.9% during the first quarter. Intech Investment Management LLC now owns 28,917 shares of the company’s stock valued at $1,135,000 after acquiring an additional 4,591 shares during the last quarter. Finally, Norges Bank bought a new stake in Twist Bioscience during the second quarter valued at $737,000.

Insiders Place Their Bets

In related news, Director Jan Johannessen sold 12,000 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $56.12, for a total value of $673,440.00. Following the transaction, the director owned 17,754 shares of the company’s stock, valued at approximately $996,354.48. This trade represents a 40.33% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Melissa A. Starovasnik sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $51.00, for a total transaction of $51,000.00. Following the completion of the transaction, the director directly owned 25,722 shares in the company, valued at approximately $1,311,822. The trade was a 3.74% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 42,768 shares of company stock worth $2,390,888 in the last 90 days. Company insiders own 3.08% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Robert W. Baird increased their price objective on shares of Twist Bioscience from $50.00 to $65.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 5th. Guggenheim increased their price objective on shares of Twist Bioscience from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Leerink Partners set a $80.00 price objective on shares of Twist Bioscience in a research report on Friday, May 22nd. Barclays increased their price objective on shares of Twist Bioscience from $55.00 to $65.00 and gave the stock an “overweight” rating in a research report on Monday, May 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research report on Friday, March 27th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $58.00.

Twist Bioscience Price Performance

Shares of NASDAQ TWST opened at $73.93 on Friday. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $80.50. The stock has a market cap of $4.60 billion, a price-to-earnings ratio of -55.59 and a beta of 2.23. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.42 and a current ratio of 2.70. The firm’s 50-day simple moving average is $56.73 and its 200 day simple moving average is $45.71.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, May 4th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.22). Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. The business had revenue of $110.72 million during the quarter, compared to the consensus estimate of $107.64 million. During the same period in the previous year, the business posted ($0.66) EPS. Twist Bioscience’s revenue was up 19.3% compared to the same quarter last year. As a group, research analysts anticipate that Twist Bioscience Corporation will post -1.86 earnings per share for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.